Waiv, a spin-out of Owkin, exists to catalyze precision medicine with clinical-grade, AI-powered tests that accelerate biomarker discovery and detection, outcome prediction, and treatment-response assessment across oncology.
Built on over seven years of validated medical-AI innovation and one of Europe’s largest multi-institutional data networks, we deliver precise, accurate, and fast analyses that support treatment decisions.
Through our industry-leading tech and AI stack, and clinically validated, already-deployed AI tests, such as RlapsRisk BC, we unlock morphological insights and future-proof both the clinical diagnostic workflow and pharmaceutical R&D pipelines, to ultimately bring scalable precision medicine to patients worldwide.